Elbasvir
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 311 publications
Rational design and relative bioperformance of high drug load grazoprevir amorphous nanoparticle formulations.
Journal: Pharmaceutical development and technology
Published: August 07, 2025
Conformational Trajectory of the Molecular Chameleon Grazoprevir from Formulation to Target-Bound.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: July 16, 2025
Molecular chameleons adaptability in target binding.
Journal: Structural dynamics (Melville, N.Y.)
Published: April 04, 2025
Targeting Telomere Shelterin Protein TPP1 with Elbasvir: Induction of Autophagy and Suppression of Esophageal Cancer Tumorigenesis.
Journal: Anti-cancer agents in medicinal chemistry
Published: March 16, 2025
Structural insight into the conversion of DhNik1, a hybrid histidine kinase from Debaryomyces hansenii to a cytotoxic phosphatase conformation for novel antifungal agent.
Journal: Journal of molecular biology
Published: January 07, 2025
Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation.
Journal: Medicinal chemistry (Shariqah (United Arab Emirates))
Published: December 26, 2024
In silico screening of potential FGF2 inhibitors for cancer therapy.
Journal: In silico pharmacology
Published: December 10, 2024
Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.
Journal: BMJ open gastroenterology
Published: November 07, 2024
Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults.
Journal: The Medical letter on drugs and therapeutics
Published: October 28, 2024
Table 3: Some drug interactions with DAAs for HCV infection.
Journal: The Medical letter on drugs and therapeutics
Published: October 28, 2024
Drugs for hepatitis C virus infection.
Journal: The Medical letter on drugs and therapeutics
Published: October 28, 2024
Last Updated: 02/24/2026